User:Mr. Ibrahem/Rivaroxaban

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

Common side effects include bleeding. Other serious side effects may include spinal hematoma and anaphylaxis. It is unclear if use in pregnancy and breastfeeding is safe. Compared to warfarin it has fewer interactions with other medications. It works by blocking the activity of the clotting protein factor Xa.

Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. It is on the World Health Organization's List of Essential Medicines as an alternative to dabigatran. In the United States, it will not be available as a generic medication until 2024. A month supply in the United Kingdom costs the NHS about £50 as of 2020. In the United States, the wholesale cost of this amount is about US$430. In 2017, it was the 109th most commonly prescribed medication in the United States, with more than six million prescriptions.